Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Recruiting 3Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Genitourinary 1CNS 1

Conditions

Sarcoma 2Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Leiomyosarcoma 1Ichthyosis, X-Linked 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
ADI PEG20 × 90 days × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT05712694 2026-04-20

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Polaris Group

Phase 3 Recruiting
300 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

NCT05813327 2026-04-20

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Washington University School of Medicine

Phase 1 Active not recruiting
6 enrolled
Sarcoma

Sarcoma, Ichthyosis, X-Linked

NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Washington University School of Medicine

Phase 1/2 Active not recruiting
31 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT06085729 2026-04-02

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡